Literature DB >> 2848044

cAMP-mediated growth inhibition of a B-lymphoid precursor cell line Reh is associated with an early transient delay in G2/M, followed by an accumulation of cells in G1.

H K Blomhoff1, R Blomhoff, T Stokke, C deLange Davies, K Brevik, E B Smeland, S Funderud, T Godal.   

Abstract

This study was undertaken to gain more insight into the effects of cyclic adenosine monophosphate (cAMP) on cell-cycle progression in the B-lymphoid precursor cell line Reh. The adenylate cyclase activator forskolin reduced the proliferation of asynchronously growing Reh cells by 50% after 72 hr culture. Growth inhibition was associated with an accumulation of cells in G1. Furthermore, we demonstrated that forskolin provoked a delay of cells for approximately 10 hr in G2/M prior to the G1 arrest. Two different methods were applied to elucidate how cells in different phases of the cell cycle were affected by an elevated cAMP level. One method was based on centrifugal elutriation, whereby synchronous cell populations from the different phases of the cell cycle were isolated. By the other method, S-phase cells were selectively stained by pulsing asynchronously growing cells with bromo-deoxyuridine (BrdU). The data demonstrate that the position of a cell in the cell cycle is critical in determining how the cell will respond to an elevated cAMP level. Thus cells in G1 at the time forskolin is added are not delayed in G2/M, but they will subsequently accumulate in G1 after 48 hr. Cells given forskolin in G2/m, however, are delayed for 10 hr in G2/M, but they do not accumulate in G1. Cells given forskolin in the S phase are delayed in G2/M as well as arrested in G1. The results suggest that cAMP inhibits growth of the Reh cells by preventing the cells from passing important restriction points located in the G1 and G2 phases of the cell cycle.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2848044     DOI: 10.1002/jcp.1041370327

Source DB:  PubMed          Journal:  J Cell Physiol        ISSN: 0021-9541            Impact factor:   6.384


  7 in total

1.  cAMP-mediated inhibition of DNA replication and S phase progression: involvement of Rb, p21Cip1, and PCNA.

Authors:  Soheil Naderi; Jean Y J Wang; Tung-Ti Chen; Kristine B Gutzkow; Heidi K Blomhoff
Journal:  Mol Biol Cell       Date:  2005-01-12       Impact factor: 4.138

2.  Activation of cAMP signaling interferes with stress-induced p53 accumulation in ALL-derived cells by promoting the interaction between p53 and HDM2.

Authors:  Elin Hallan Naderi; Aart G Jochemsen; Heidi Kiil Blomhoff; Soheil Naderi
Journal:  Neoplasia       Date:  2011-07       Impact factor: 5.715

3.  cAMP signaling induces rapid loss of histone H3 phosphorylation in mammary adenocarcinoma-derived cell lines.

Authors:  Pedro Rodriguez-Collazo; Sara K Snyder; Rebecca C Chiffer; Jordanka Zlatanova; Sanford H Leuba; Catharine L Smith
Journal:  Exp Cell Res       Date:  2007-09-22       Impact factor: 3.905

4.  Regulation of the expression of lactate dehydrogenase isozymes in human lymphocytes.

Authors:  P Wollberg; B D Nelson
Journal:  Mol Cell Biochem       Date:  1992-03-25       Impact factor: 3.396

5.  cAMP signaling regulates histone H3 phosphorylation and mitotic entry through a disruption of G2 progression.

Authors:  Pedro Rodriguez-Collazo; Sara K Snyder; Rebecca C Chiffer; Erin A Bressler; Ty C Voss; Eric P Anderson; Hans-Gottfried Genieser; Catharine L Smith
Journal:  Exp Cell Res       Date:  2008-07-08       Impact factor: 3.905

6.  Cyclic AMP induces apoptosis in multiple myeloma cells and inhibits tumor development in a mouse myeloma model.

Authors:  Virginie Follin-Arbelet; Peter O Hofgaard; Harald Hauglin; Soheil Naderi; Anders Sundan; Rune Blomhoff; Bjarne Bogen; Heidi K Blomhoff
Journal:  BMC Cancer       Date:  2011-07-18       Impact factor: 4.430

7.  Inhibition of Glioma Cell Growth and Apoptosis Induction through Targeting Wnt10B Expression by Pyrazolo[4,3-c]pyridine-4-one.

Authors:  Yang Liu; Zhu Yaozu; Huang Zhao; Peng Peng; Zhang Tingbao; Chen Jincao
Journal:  Med Sci Monit       Date:  2020-11-11
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.